Our Scientific Advisors include renowned global academic and clinical leaders in diseases of the gastrointestinal tract, liver and pancreas, including cholangiopathies and cancers.
Professor Massimo Pinzani, MD, PhD, FAASLD
Massimo Pinzani co-founded Engitix in 2016 and serves on the Board of Directors. He is Professor of Medicine and Director of the UCL Institute for Liver and Digestive Health (ILDH), and the Sheila Sherlock Chair of Hepatology at UCL, London. He is a clinical and translational hepatologist, renowned globally as an academic leader in liver fibrosis and HCC.
Mario Strazzabosco, MD, PhD
Mario Strazzabosco is Professor of Medicine (Digestive Diseases) at the Yale Medical School and the Director and Clinical Program Leader of the Smilow Liver Cancer Program and the Deputy Director of the Yale Liver Center, New Haven, USA. He is internationally recognised as an expert in advanced hepatology and liver cancer.
Tom Hemming Karlsen, MD, PhD
Tom Hemming Karlsen is Full Professor of Internal Medicine, Department of Transplantation Medicine, Oslo University Hospital Rikshospitalet and University of Oslo, Norway. He is a former Secretary General of EASL, Geneva, Switzerland and his specialism is cholangiopathies (PSC).
Doug Thorburn, MD
Doug Thorburn is Professor of Medicine at the UCL Institute for Liver and Digestive Health London, UK. He is Clinical Director for the Liver Transplantation, HPB, Hepatology, Endoscopy and Gastroenterology services at the Royal Free Hospital with a research focus in autoimmune and cholestatic liver diseases.
Giuseppe Fusai, MD
Giuseppe Fusai is a Professor of Surgery at UCL and a consultant hepatic pancreatic biliary surgeon and President of the Italian Medical Society of Great Britain. His primary clinical and academic interest is in oncological surgery and treatment modalities for patients with advanced disease.
Tu Vinh Luong, MD
Tu Vinh Luong is Consultant Liver, HPB and GI Histopathologist at the Royal Free Hospital, London, and Honorary Senior Lecturer at the UCL Institute for Liver and Digestive Health, London. She is a member of the UCL-RFH Biobank Ethical Review Committee (B-ERC-RFH). Special research interests include liver fibrosis, steatosis and HCC.
Gerhard Niederfellner, PhD
A molecular and cellular biologist by training, Gerhard Niederfellner has worked in the pharma industry for ~20 years at Eli Lilly, Roche and Ablynx. He spent 9 years with Roche, latterly heading the department of tumour cell biology, developing biologics for cancer therapy, including many mono- and multi-specific antibodies.
Melissa Palmer, MD
Melissa Palmer is a renowned hepatologist and experienced biopharmaceutical executive, currently the Head of Liver Disease Development at Takeda. She worked for ~25 years as a hepatologist before moving to Kadmon Pharmaceuticals then Shire. She has a BA from Columbia and trained in Medicine and Hepatology at Mount Sinai Medical School.